INmune Bio Awarded a $1 Million Grant for the Development of XPro1595 for the treatment of Alzheimer’s Disease
February 11 2019 - 8:00AM
The Alzheimer’s Association awarded INmune Bio
the Part the Cloud to RESCUE grant to target neuroinflammation in
Alzheimer’s Disease
INmune Bio, Inc. (NASDAQ: INMB), an immunotherapy company focused
on developing treatments that harness the patient’s innate immune
system to fight disease, today announced that it has been awarded a
grant to receive $1,000,000 from the Alzheimer's Association to
advance XPro1595, a novel therapy targeting neuroinflammation as a
cause of Alzheimer’s disease. The endowment was awarded under the
Part the Cloud to RESCUE grant. The $1,000,000 award will be paid
to the Company in traches over the course of the Phase 1 clinical
trial.
“We are honored to receive this grant from the
Alzheimer’s Association,” said RJ Tesi, M.D., CEO of INmune Bio.
“The Alzheimer’s Association has shown the vision and leadership to
support the quest for effective therapies beyond traditional
targets. As an immunology company, we focus on the role that innate
immune dysregulation and neuroinflammation play in the progression
of Alzheimer’s. This grant allows us to enter clinical trials –
something that would not have been possible without the
organization’s generous support.”
“Today, 50 million people worldwide are living
with Alzheimer’s and related dementias, a truly astounding number
that continues to grow with the aging global population,” said CJ
Barnum, Ph.D., Director of Neuroscience for INmune Bio. “XPro1595
has been shown to inhibit microglial activation, part of the
pathophysiology of neuroinflammation, in animal models of
neurodegenerative disease. This Phase I trial will translate those
findings into patients.” For more information about the Part the
Cloud grants, please visit:
https://www.alz.org/partthecloud/overview.asp
For more information about the Alzheimer’s
Association, please visit:https://www.alz.org/
About INmune Bio, Inc.INmune
Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage
biotechnology company developing therapies targeting the innate
immune system in cancer. INmune Bio is developing two products
platforms that reengineer the patient’s innate immune system’s
response to their cancer, INKmune and INB03. INKmune is a Natural
Killer (NK) cell therapeutic that primes the patient’s NK cells to
attack developing disease. INB03 inhibits myeloid derived
suppressor cells (MDSC), which often cause resistance to
immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio’s
product platforms target residual disease and utilize a precision
medicine approach for treatment of a wide variety of hematologic
malignancies and solid tumors. To learn more, please visit
www.inmunebio.com.
INmune Bio Contact: David Moss,
CFO(858) 964-3720DMoss@INmuneBio.com
Media Contact: Antenna GroupNechama
Feuerstein(201) 373-2228INmuneBio@AntennaGroup.com
Ascent Investor Relations:Tina XiaoPresident
(917) 609-0333tina.xiao@ascent-ir.com
Investors:LHA Investor RelationsMiriam Weber
MillerSenior Vice President(212) 838-3777mmiller@lhai.com
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Mar 2024 to Apr 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Apr 2023 to Apr 2024